#ACR2022 Year in Review. Dr Varga highlighted work by @GeorgeTsokos. In #lupus mice, adding CD38-i in a CD8+ T cell–targeted manner improved effector function, reversed the defects and improved viral clearance. CD38 as a target could reduce infection in SLE @rheumnow https://t.co/XlmvysjkDP

Ab0344 #ACR22 CKD2+ a/w incr HCQ levels by 149 ng/mL vs CKD1 400 mg/d dose: incr HCQ levels by 448 ng/mL vs 200 Incr body wt by 15 kg -> decr HCQ levels by 82 ng/mL Social determinants didn't effect data >750ng/mL and >1000 predicted of 75% decr flare risk @Rheumnow #ACRBest https://t.co/p21rqnO4ym

Abstr 0373 created a scoring system to predict outcomes in SpA pts w/ uveitis - Poor outcomes seen among smoking hx, females, +HLAB27, axial & peripheral involvement, high disease activity, inflammation, and b/l eye involvement https://t.co/mGAn0Eel1O @RheumNow #ACR22 https://t.co/qtJsavtG9z

• Factors Associated with Adverse Outcomes in Uveitis Related to Spondylarthritis…

New 2022 EULAR Recommendations for the Management of RA The updated '22 EULAR recommendations for the mgmt of RA were initially presented at EULAR '22, and are now in press delineating the most recent developments and perspectives in RA treatment. https://t.co/xnpOUnpgvy https://t.co/OWcRq7nZ57

• https://bit.ly/3TsSWKQ

Talking a lot about CAR-T these days! Upcoming @Figure1 newsletter, blog post @RheumNow, and interview w/@MaxKonigMD comping soon! I'm actually skeptical of this in SLE; are B cells really the answer? w/better targeting & dx selection, this could be game changing #ACR22 https://t.co/Z6t99ZIeMy

A group of older patients w/ multimorbidity (5+) drives higher mortality risk in RA. Crowson et al. stratification 4 clusters. Each cluster = different outcome, younger cluster w/ few comorbidities = no > mortality https://t.co/IYccicjcyy Abstr #0246 #ACR22 @Rheumnow #ACRBest https://t.co/ee9sgG3g0l

• Comorbidity Clusters in Patients with Rheumatoid Arthritis Predict Survival Pro…

2022 has been a great year for development of novel therapies in Phase 2 RCTs in #lupus as highlighted by Dr Langford #ACR22 Year In Review. I'd add Deucravacitinib to those lists. Look forward to Phase 3 results soon @RheumNow https://t.co/yH25KFDGdd

Year in review #ACR22 IV Tocilizumab FDA approved in GCA!! Randomized trial of iv tocilizumab in PMR - 101 pts. Steroid taper was quicker. https://t.co/BQT2H8LEFk @rheumnow https://t.co/4KAYrz1IES

• Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia R…

Very helpful slide on the different MOAs of JAK inhibitors (by Lui C et al.) shared by Dr. Langford #ACR22 @RheumNow #RheumTwitter #yearinreview https://t.co/9VIOmzNoMq

VEXAS is more common than you think in men >50 #ACR22 https://t.co/z2T6nBoI9a

Yr in review #ACR22 @RheumNow 🌟GLORIA 2 yr data: 👉Pred 5mg OD vs PBO >65y/o RA ✅⬇️ disease activity (DAS28 -0.38) ✅⬇️ joint damage (sharp/van der heijde -1.7) ❌ 24% ⬆️ a/e “Weigh success in benefit and failure in harm 2 individualise use of low dose pred in RA >65y/o”

CAR T cell therapy for treatment of lupus Small sample size of 5 pts, but improvement in all pts, 4 achieving SLEDAI =0 Note - cytokine release syndrome in 3 pts. Excellent overview of CAR T cell therapy and its complexity! @RheumNow #ACR22 https://t.co/3PP14tVudb

MTX increases pegloticase efficacy in MIRROR trial. Similar safety too. Shame the cost of pegloticase is prohibitive in Australia... @RheumNow #ACR22 #yearinreview